Compass Therapeutics (CMPX) Retained Earnings (2023 - 2025)
Compass Therapeutics (CMPX) has disclosed Retained Earnings for 3 consecutive years, with -$431.2 million as the latest value for Q4 2025.
- Quarterly Retained Earnings fell 205420.0% to -$431.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$431.2 million through Dec 2025, down 205420.0% year-over-year, with the annual reading at -$431.2 million for FY2025, 205420.0% down from the prior year.
- Retained Earnings hit -$431.2 million in Q4 2025 for Compass Therapeutics, down from $274000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $274000.0 in Q3 2025 to a low of -$431.2 million in Q4 2025.
- Historically, Retained Earnings has averaged -$198.8 million across 3 years, with a median of -$291.3 million in 2023.
- Biggest YoY gain for Retained Earnings was 328.57% in 2025; the steepest drop was 205420.0% in 2025.
- Year by year, Retained Earnings stood at -$315.3 million in 2023, then soared by 100.07% to $210000.0 in 2024, then plummeted by 205420.0% to -$431.2 million in 2025.
- Business Quant data shows Retained Earnings for CMPX at -$431.2 million in Q4 2025, $274000.0 in Q3 2025, and $208000.0 in Q2 2025.